Loading…
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $344M | $11M | $-24M | $28M | -5.1% | 3.7% | -232.4% |
| 2024 | $332M | $38M | $18M | $37M | 4.0% | 51.1% | - |
| 2023 | $220M | $-45M | $-57M | $-19M | -14.7% | 60.4% | - |
| 2022 | $137M | $-58M | $-67M | $-47M | -16.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 137.04 | 219.79 | 332.07 | 344.23 |
| Cost Of Revenue | 32.01 | 44.98 | 60.20 | 71.03 |
| Gross Profit | 105.03 | 174.81 | 271.86 | 273.20 |
| Operating Expense | 196.17 | 242.78 | 263.19 | 316.01 |
| Operating Income | -91.14 | -67.98 | 8.67 | -42.81 |
| EBITDA | -58.34 | -45.02 | 38.14 | 11.34 |
| EBIT | -68.89 | -57.35 | 22.14 | -29.43 |
| Pretax Income | -68.90 | -57.37 | 21.56 | -29.51 |
| Tax Provision | -1.77 | 0.10 | 3.32 | -5.36 |
| Net Income | -67.14 | -57.47 | 18.25 | -24.16 |
| Net Income Common Stockholders | -67.14 | -57.47 | 18.25 | -24.16 |
| Total Expenses | 228.18 | 287.76 | 323.40 | 387.04 |
| Interest Expense | 0.02 | 0.01 | 0.58 | 0.09 |
| Interest Income | 3.97 | 10.62 | 12.92 | 11.77 |
| Research And Development | 44.90 | 53.62 | 52.04 | 51.85 |
| Selling General And Administration | 143 | 180.15 | 200.05 | 229.32 |
| Normalized EBITDA | -76.63 | -45.02 | 37.58 | 9.88 |
| Normalized Income | -84.96 | -57.47 | 17.78 | -25.36 |
| Basic EPS | -2.58 | -2.14 | 0.66 | -0.83 |
| Diluted EPS | -2.58 | -2.14 | 0.62 | -0.83 |
| Tax Effect Of Unusual Items | 0.47 | 0 | 0.09 | 0.27 |
| Tax Rate For Calcs | 0.03 | 0.21 | 0.15 | 0.18 |
| Total Unusual Items | 18.29 | 0 | 0.56 | 1.47 |
| Total Unusual Items Excluding Goodwill | 18.29 | 0 | 0.56 | 1.47 |
| Net Income From Continuing Operation Net Minority Interest | -67.14 | -57.47 | 18.25 | -24.16 |
| Reconciled Depreciation | 10.54 | 12.33 | 16 | 40.77 |
| Reconciled Cost Of Revenue | 29.73 | 41.66 | 55.31 | 65.09 |
| Net Interest Income | 3.95 | 10.61 | 12.34 | 11.69 |
| Net Income From Continuing And Discontinued Operation | -67.14 | -57.47 | 18.25 | -24.16 |
| Total Operating Income As Reported | -72.86 | -67.98 | 8.67 | -42.81 |
| Diluted Average Shares | 26.05 | 26.80 | 29.25 | 28.99 |
| Basic Average Shares | 26.05 | 26.80 | 27.78 | 28.99 |
| Diluted NI Availto Com Stockholders | -67.14 | -57.47 | 18.25 | -24.16 |
| Net Income Including Noncontrolling Interests | -67.14 | -57.47 | 18.25 | -24.16 |
| Net Income Continuous Operations | -67.14 | -57.47 | 18.25 | -24.16 |
| Other Income Expense | 18.29 | 0 | 0.56 | 1.61 |
| Other Non Operating Income Expenses | 0 | 0 | 0.56 | 0.14 |
| Special Income Charges | 18.29 | 0 | 0 | 0 |
| Restructuring And Mergern Acquisition | -18.29 | 0 | 0 | 0 |
| Gain On Sale Of Security | 0 | 0 | 0.56 | 1.47 |
| Net Non Operating Interest Income Expense | 3.95 | 10.61 | 12.34 | 11.69 |
| Interest Expense Non Operating | 0.02 | 0.01 | 0.58 | 0.09 |
| Interest Income Non Operating | 3.97 | 10.62 | 12.92 | 11.77 |
| Depreciation Amortization Depletion Income Statement | 8.27 | 9.01 | 11.11 | 34.84 |
| Depreciation And Amortization In Income Statement | 8.27 | 9.01 | 11.11 | 34.84 |
| Amortization | 8.27 | 9.01 | 11.11 | 34.84 |
| Amortization Of Intangibles Income Statement | 8.27 | 9.01 | 11.11 | 34.84 |
| Selling And Marketing Expense | 86.61 | 113.66 | 123.47 | 138.12 |
| General And Administrative Expense | 56.40 | 66.50 | 76.58 | 91.21 |
| Other Gand A | 56.40 | 66.50 | 76.58 | 91.21 |
| Operating Revenue | 137.04 | 219.79 | 332.07 | 344.23 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Castle Biosciences, Inc.this co. | CSTL | $734M | - | 1.53 | -5.1% | -224.72 |
| ARS Pharmaceuticals, Inc. | SPRY | $778M | - | 6.81 | -149.9% | -3.94 |
| BioAge Labs, Inc. | BIOA | $749M | - | 2.32 | -29.6% | -5.11 |
| Absci Corporation | ABSI | $732M | - | 3.77 | -60.8% | -5.15 |
| CBLL | CBLL | $729M | - |
| 4.65 |
| -34.4% |
| -10.30 |
| Allogene Therapeutics, Inc. | ALLO | $726M | - | 1.65 | -65.3% | -1.79 |
| Gyre Therapeutics, Inc. | GYRE | $713M | 367.50 | 6.33 | 3.5% | 46.81 |
| Enhabit, Inc. | EHAB | $704M | - | 1.31 | -0.8% | 13.72 |
| Solid Biosciences Inc. | SLDB | $694M | - | 3.09 | -96.8% | -2.97 |
| Peer Median | - | 367.50 | 3.43 | -47.6% | -3.46 | |